TY - JOUR
T1 - AMPKα1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism
AU - Dufeys, Cécile
AU - Daskalopoulos, Evangelos Panagiotis
AU - Castanares-Zapatero, Diego
AU - Conway, Simon J.
AU - Ginion, Audrey
AU - Bouzin, Caroline
AU - Ambroise, Jérôme
AU - Bearzatto, Bertrand
AU - Gala, Jean Luc
AU - Heymans, Stephane
AU - Papageorgiou, Anna Pia
AU - Vinckier, Stefan
AU - Cumps, Julien
AU - Balligand, Jean Luc
AU - Vanhaverbeke, Maarten
AU - Sinnaeve, Peter
AU - Janssens, Stefan
AU - Bertrand, Luc
AU - Beauloye, Christophe
AU - Horman, Sandrine
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - We have previously demonstrated that systemic AMP-activated protein kinase α1 (AMPKα1) invalidation enhanced adverse LV remodelling by increasing fibroblast proliferation, while myodifferentiation and scar maturation were impaired. We thus hypothesised that fibroblastic AMPKα1 was a key signalling element in regulating fibrosis in the infarcted myocardium and an attractive target for therapeutic intervention. The present study investigates the effects of myofibroblast (MF)-specific deletion of AMPKα1 on left ventricular (LV) adaptation following myocardial infarction (MI), and the underlying molecular mechanisms. MF-restricted AMPKα1 conditional knockout (cKO) mice were subjected to permanent ligation of the left anterior descending coronary artery. cKO hearts exhibit exacerbated post-MI adverse LV remodelling and are characterised by exaggerated fibrotic response, compared to wild-type (WT) hearts. Cardiac fibroblast proliferation and MF content significantly increase in cKO infarcted hearts, coincident with a significant reduction of connexin 43 (Cx43) expression in MFs. Mechanistically, AMPKα1 influences Cx43 expression by both a transcriptional and a post-transcriptional mechanism involving miR-125b-5p. Collectively, our data demonstrate that MF-AMPKα1 functions as a master regulator of cardiac fibrosis and remodelling and might constitute a novel potential target for pharmacological anti-fibrotic applications.
AB - We have previously demonstrated that systemic AMP-activated protein kinase α1 (AMPKα1) invalidation enhanced adverse LV remodelling by increasing fibroblast proliferation, while myodifferentiation and scar maturation were impaired. We thus hypothesised that fibroblastic AMPKα1 was a key signalling element in regulating fibrosis in the infarcted myocardium and an attractive target for therapeutic intervention. The present study investigates the effects of myofibroblast (MF)-specific deletion of AMPKα1 on left ventricular (LV) adaptation following myocardial infarction (MI), and the underlying molecular mechanisms. MF-restricted AMPKα1 conditional knockout (cKO) mice were subjected to permanent ligation of the left anterior descending coronary artery. cKO hearts exhibit exacerbated post-MI adverse LV remodelling and are characterised by exaggerated fibrotic response, compared to wild-type (WT) hearts. Cardiac fibroblast proliferation and MF content significantly increase in cKO infarcted hearts, coincident with a significant reduction of connexin 43 (Cx43) expression in MFs. Mechanistically, AMPKα1 influences Cx43 expression by both a transcriptional and a post-transcriptional mechanism involving miR-125b-5p. Collectively, our data demonstrate that MF-AMPKα1 functions as a master regulator of cardiac fibrosis and remodelling and might constitute a novel potential target for pharmacological anti-fibrotic applications.
KW - AMPKα1
KW - Cardiac fibroblast
KW - Cardiac fibrosis
KW - Connexin 43
KW - miR-125b-5p
KW - Myofibroblast
UR - http://www.scopus.com/inward/record.url?scp=85100769326&partnerID=8YFLogxK
U2 - 10.1007/s00395-021-00846-y
DO - 10.1007/s00395-021-00846-y
M3 - Article
C2 - 33564961
AN - SCOPUS:85100769326
SN - 0300-8428
VL - 116
JO - Basic Research in Cardiology
JF - Basic Research in Cardiology
IS - 1
M1 - 10
ER -